Earnings summaries and quarterly performance for Turn Therapeutics.
Research analysts covering Turn Therapeutics.
Recent press releases and 8-K filings for TTRX.
Turn Therapeutics Provides Corporate and Pipeline Updates and 2026 Outlook
TTRX
Board Change
New Projects/Investments
Guidance Update
- The Phase 2 trial of GX-03 for moderate-severe atopic dermatitis is on track, with both interim analysis and topline data expected in the first half of 2026.
- Martin Dewhurst, an M&A veteran with over 30 years of experience, has been appointed to the Company's Board of Directors.
- Turn Therapeutics expanded its vaccine pipeline to include an intranasal Influenza candidate, with in-vivo and in-vitro studies anticipated to begin in the first quarter of 2026.
- A strategic partnership with Medline is expected to generate near-term revenue in 2026 in the advanced wound care market.
- The company has strengthened its balance sheet, extending its operational runway into late 2026.
Jan 12, 2026, 1:12 PM
Turn Therapeutics Appoints Martin Dewhurst to Board of Directors
TTRX
Board Change
New Projects/Investments
Executive Compensation
- Turn Therapeutics Inc. (TTRX) appointed Martin Dewhurst to its Board of Directors on January 7, 2026, expanding the Board from five to six members. Mr. Dewhurst brings over 30 years of life sciences and M&A experience and will chair the compensation committee.
- This appointment aligns with the company's M&A-focused strategy to expand its pipeline and accelerate long-term value creation.
- The company's lead product candidate, GX-03, is currently in a Phase 2 trial for moderate-to-severe eczema, with an interim analysis projected for Q1 2026 and topline data readout in Q2 2026. GX-03 is also Phase 3 ready for onychomycosis.
- Turn Therapeutics has existing partnerships that include over $70 million in milestone payments plus royalties from FDA-cleared products.
- The company's average monthly cash burn was $2,924,000 in 2023, $115,000 in 2024, and $113,000 for the first nine months of 2025.
Jan 7, 2026, 9:18 PM
Turn Therapeutics Enters Global Supply, Development, and License Agreement with Medline
TTRX
New Projects/Investments
Product Launch
- Turn Therapeutics Inc. (TTRX) announced on October 30, 2025, that it has entered into a global supply, development, and license agreement with Medline, the largest provider of medical-surgical products and supply chain solutions.
- This collaboration will leverage Turn's proprietary PermaFusion® delivery platform for the development, manufacturing, and commercialization of products.
- The partnership is expected to accelerate Turn's entry into professional and consumer markets by utilizing Medline's global scale and distribution capabilities.
- Financial terms, specific product categories, and development timelines of the agreement remain confidential.
Oct 30, 2025, 11:44 AM
Turn Therapeutics Inc. Enters Global Supply, Development, and License Agreement with Medline Industries
TTRX
New Projects/Investments
Product Launch
Revenue Acceleration/Inflection
- Turn Therapeutics Inc. (TTRX) entered into a Global Supply, Development, and License Agreement with Medline Industries, LP, effective October 23, 2025.
- This agreement establishes a multi-year framework for the development, manufacturing, and global commercialization of professional and consumer health products leveraging Turn's proprietary PermaFusion® delivery platform.
- Medline will lead global commercialization and distribution across its professional and retail networks in more than one hundred countries and territories.
- The initial term of the agreement is three years, with automatic one-year renewals.
Oct 28, 2025, 8:05 PM
Turn Therapeutics Inc. Completes Direct Listing and Enters Key Agreements
TTRX
Delisting/Listing Issues
Executive Compensation
New Projects/Investments
- Turn Therapeutics Inc.'s registration statement on Form S-1 for its direct listing on the Nasdaq Global Market was declared effective by the SEC on September 30, 2025. Registered stockholders may offer and sell up to 17,868,760 shares of Common Stock.
- In connection with the direct listing, the company entered into a Stockholders Agreement on September 11, 2025, with its founder and CEO, Bradley Burnam, and BEB Holdings, LLC (the "Holders"). This agreement requires the Holders' consent for certain corporate actions, including mergers, significant asset acquisitions, equity issuances over $50 million, and changes to senior management compensation over $200,000.
- The company also entered into employment agreements on September 15, 2025, with Bradley Burnam and Zuraiz Chaudhary, which became effective with the direct listing.
- The compensation for Bradley Burnam is as follows: | Metric | Bradley Burnam | |---|---| | Annual Base Salary ($USD) | $575,000 | | Target Annual Bonus (% of Base Salary) | 50% | | Target Annual Equity Awards (% of Base Salary) | 50% |
- The company's capital structure includes 500,000,000 shares of Common Stock and 100,000,000 shares of Preferred Stock authorized, each with a par value of $0.0001. A two-for-one stock split of Common Stock became effective with the amended and restated certificate of incorporation.
Oct 2, 2025, 6:15 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more